DIAGNOS Announces Private Placement of Common Stocks and Stock Warrants
Momentum Public Relations
Press Release: November 6, 2018
DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (“Private Placement”) of up to 16,160,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of up to $808,000. Each Unit consists of;
- one common share (“Share”), and
- one stock warrant (“Warrant”) entitling the holder to purchase one Share per Warrant at a price of $0.05 per Share, for a period of 24 months from the date of issuance of the Warrant.
The proceeds will be used mainly to fund sales and marketing as well as administrative expenses.
It is expected that one participant in the Private Placement will become a “related party” of DIAGNOS within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). It is expected that 15,000,000 Units will be subscribed by the participant. The participant will exercise, as a result of the Private Placement, control up to 19.10% of the common shares of DIAGNOS. The transaction is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101 based on the fact that the fair market value of the related party’s participation in the Private Placement does not exceed 25% of DIAGNOS’ market capitalization prior to the closing of the Private Placement.
Shares issued as part of the Private Placement as well as the underlying Shares to be issued upon exercise of the Warrants are subject to a statutory four-month hold period from the date of issuance.
Closing of the Private Placement is scheduled for November 9, 2018. The Private Placement is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
- Published in Business, Diagnos, Life Sciences, News Home, Technology
ATW Tech Announces Signature of a Letter of Intent for Major Acquisition of Greywolf Entertainment Group
Momentum Public Relations
Press Release: November 6, 2018
ATW Tech Inc. (“ATW Tech”) (TSX-V: ATW) announces today the signature of a letter of intent for the acquisition from Fastrack Trust (the “Trust”) of all of the outstanding shares of 6855318 Canada Ltd. and 6890202 Canada Ltd. (“Greywolf Entertainment Group” or “Greywolf”).
Greywolf Entertainment Group, based in Calgary, provides turnkey full commercial production for interactive TV and/or voting networks required for such shows for landline and mobile consumers. Greywolf’s subsidiaries include Triton Global Business Services Inc. (“Triton”) and Fastrack Global Billing Networks Inc. (“Fastrack”). Triton is a North American clearinghouse that provide billing and networks for phone bills in North America and over 40 other countries. Triton has been listed in the top 300 technology companies from Canada several times. Fastrack is a North American inter-exchange carrier providing networks to its switch centers that intelligently routes consumer traffic to optimized billing or response solutions. Its network is designed to handle mass calling for both short and long periods of time, using its own robust backbone Standard Internet Protocol (SIP) networks to transport traffic anywhere in the world. For the unaudited financial year ended December 31, 2017, Greywolf’s revenues were $10.0 million.
The letter of intent contemplates a purchase price of $2.95 million, which is subject to certain adjustments and payable through a cash payment of $2.0 million at closing, a vendor take-back note of $0.3 million payable in 30 equal monthly installments and $0.65 million worth of common shares of ATW Tech. No commission is payable and no change of control will result.
“We are proud to come to an agreement on this strategic acquisition of Greywolf that will help us consolidate our position in the Canadian carrier billing market, accelerate our growth, while almost doubling our revenues, and benefiting from significant cost synergies. Along with the contemplated divestiture of the Atman division announced on September 17, 2018, which represented 9.5% of ATW Tech’s revenues in 2017, this contemplated acquisition reflects our will and strategy to concentrate our activities on our core integrated payment, interactive communication and voting platforms. This acquisition shall be the first step of our acquisition growth plan with an international reach expected for 2019” said Michel Guay, President and CEO of ATW Tech.
The closing of this transaction between ATW Tech and Greywolf, which are dealing at arm’s length, is conditional among other things on ATW Tech carrying out a satisfactory due diligence on Greywolf, obtaining satisfactory financing and all necessary regulatory approvals. Closing of this transaction is expected before the end of 2018.
Update on PlusMobile Acquisition
In August 2017, ATW Tech announced the signature of a letter of intent for the contemplated acquisition of PlusMobile LLC (“PlusMobile”) and all of its subsidiaries. PlusMobile is based in Argentina and offers premium products on mobile phones with carrier billing agreements in 6 countries of Latin America and offers quality contents such as mobile apps in the business segments of education, kids, entertainment as well as mobile marketing via SMS. Although ATW Tech’s goal is still to expand its distribution network and diversify its operations internationally, especially in the Latin America fast growing carrier billing market, ATW Tech has decided to put that contemplated acquisition on hold temporarily due to the recent volatility in the Argentina economy and in particular in the local currency. ATW Tech will revisit in due course if and when market conditions warrant.
Forward-Looking Statements Disclaimer
Certain statements in this press release may be forward-looking. Such statements include those with respect to the closing of the acquisition of Greywolf and ATW Tech’s growth and acquisition strategy. Although ATW Tech believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurances that its expectations will be achieved. Such assumptions, which may prove incorrect, include the following: (i) the conditions for the transaction will be met, including a satisfactory due diligence by ATW Tech on Greywolf and ATW Tech securing financing on satisfactory terms, (ii) ATW Tech and the Trust will successfully negotiate and enter into a purchase agreement and other documents relating to the transaction, (iii) ATW Tech will successfully obtain the necessary regulatory approvals for the acquisition of Greywolf on commercially-acceptable terms, (iv) the acquisition of Greywolf will allow ATW Tech to achieve the anticipated cost synergies and (v) ATW Tech will successfully identify and conclude additional acquisitions outside of Canada in 2019. A description of other risks affecting ATW Tech’s business and activities appears under the heading “Risks Factors and Uncertainty” on pages 9 and 10 of ATW Tech’s 2017 annual management’s discussion and analysis, which is available on SEDAR at www.sedar.com. No assurance can be given that any events anticipated by the forward-looking information in this press release will transpire or occur, or if any of them do so, what benefits that ATW Tech will derive therefrom. ATW Tech disclaims any intention or obligation to update or revise any forward-looking statements in order to account for any new information or any other event, except as required under applicable law. The reader is warned against undue reliance on these forward-looking statements.
Additional information regarding ATW Tech is available on SEDAR www.sedar.com
- Published in Atmanco, Financial Technology, News Home, Technology
ATW Tech Closes the Sale of its Atman Assets for $1.3 Million
Momentum Public Relations
Press Release: November 1, 2018
ATW Tech Inc. (TSX-V: ATW) announces today the closing of the sale of its Psychometric Research and Services of Atman assets (“Atman”), previously announced on September 17, 2018. Those assets consist primarily of the personality test platforms and learning modes offered to businesses for human resources management. The total purchase price is $1,300,000, composed of $1,100,000 paid immediately in cash and $200,000 as monthly installments over the next 3 years and based on a percentage of sales. ATW Tech will pay to the buyer a total of $95,000 in twelve equal monthly instalments for its working capital. For the fiscal year ended December 31, 2017, revenues generated by the Atman assets being sold represented 9.6% of ATW Tech’s revenues.
“We are proud to conclude this transaction, and especially to do so within the expected timeline. This transaction reflects our will and strategy to concentrate all our activities and resources on our financial technologies (“fintech”)” said ATW Tech’s President and CEO, Michel Guay.
Additional information regarding the Company is available on SEDAR www.sedar.com. The TSX Venture Exchange and its Regulatory Services provider (as per meaning assigned to this term in TSX Venture Exchange’s policies) bear no liability as to the relevance or accuracy of this press release.
ABOUT ATW TECH
ATW Tech (TSX-V: ATW) is a leader in information technology, owner of several web platforms including VoxTel, VuduMobile, Option.vote and Bloomed. VoxTel offers various interactive communication and landline and mobile carrier billing phone solutions. VuduMobile is specialized the text messaging business for enterprises through its unique, user-friendly and bilingual test messaging application et turnkey solution allowing management of text message management programs in all kind of businesses. Option.vote offers a large scale customizable and secured multi-method voting system for unions, political parties, professional associations, and others looking for a way to reduce their voting costs and to improve their participation rates. Bloomed is a cloud-based platform to manage data (smart data) on consumers and their behaviors which is developed for marketing agencies and their campaigns for the consumer and corporate markets.
SOURCE:
ATW Tech Michel Guay Founder, president and CEO Tel.: 514.935.5959 ext. 301 mguay@atwtech.com www.atwtech.com |
Simon Bédard, CA, CPA, CFA, MBA CFO Tel. : 514.935.5959 ext. 304 sbedard@atmanco.com |
- Published in Atmanco, Business, Financial Technology, News Home, Technology
DIAGNOS Announces Private Placement of Common Stocks and Shares for Debt
Momentum Public Relations
Press Release: October 24, 2018
DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (“Private Placement”) of up to 8,000,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of up to $400,000. The Corporation also announces its intention to issue 4,375,000 common shares in payment for a debt of $218,750 related to interests payable on outstanding convertible debentures and convertible notes.
Private Placement
Each Unit consists of;
(i) | one common share (“Share”), and |
(ii) | one stock warrant (“Warrant”) entitling the holder to purchase one Share per Warrant at a price of $0.07 per Share, for a period of 18 months from the date of issuance of the Warrant. |
The proceeds will be used mainly to fund sales and marketing as well as administrative expenses.
One participant in the Private Placement is a director of DIAGNOS and, therefore, considered a “related party” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The director is expected to subscribe for up to 2,000,000 Units and, together with one related person, would exercise, as a result of the Private Placement, control over 5.15% of the common shares of DIAGNOS. The transaction is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101 based on the fact that the fair market value of the related party’s participation in the Private Placement does not exceed 25% of DIAGNOS’ market capitalization prior to the closing of the Private Placement.
Shares issued as part of the Private Placement as well as the underlying Shares to be issued upon exercise of the Warrants are subject to a statutory four-month hold period from the date of issuance.
Closing of the Private Placement is scheduled for October 30, 2018. The Private Placement is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.
Shares for debt
The Corporation intends to issue 4,375,000 common shares at a deemed price of $0.05 in payment for a debt of $218,750 related to interests payable on outstanding convertible debentures and convertible notes.
Satisfying this outstanding indebtedness with shares was undertaken in order to preserve the Corporation’s cash for operational purposes.
One participant eligible to receive common shares as part of the shares for debt arrangement is a director of DIAGNOS and, therefore, considered a “related party” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The director, together with one related person, is expected to receive 230,000 common shares. The transaction is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101 based on the fact that the fair market value of the related party’s participation in the shares for debt arrangement does not exceed 25% of DIAGNOS’ market capitalization. Shares issued to the director and one certain related person, as part of the shares for debt arrangement, are subject to a statutory four-month hold period from the date of issuance.
The issuance of shares as part of the shares for debt transaction is subject to receipt of approvals from all of the parties, as well as from the applicable regulatory authorities, including the approval of the TSX Venture Exchange, and the execution of formal documentation.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
- Published in Business, Diagnos, Life Sciences, News Home, Technology
MedX Health adds Stockfleth to medical advisory board
Momentum Public Relations
Press Release: October 23, 2018
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany has agreed to join MedX’s Medical Advisory Board. Dr. Stockfleth was previously the Director of the Skin Cancer Center in Berlin.
“The addition of Dr. Stockfleth to our Medical Advisory Board completes our group of highly accomplished physicians from around the world. They are respected thought leaders located in our targeted markets. We are very fortunate to have access to Dr. Stockfleth’s knowledge and expertise,” said Scott Spearn, CEO of MedX.
“MedX’s non-invasive skin cancer scanning technology is ground-breaking and I am honored to be a member of such an esteemed group of physicians,” Dr. Stockfleth said. “I see first-hand how MedX’s technology is a game-changer in early detection of skin cancers,” he added. He noted that his clinic in Bochum receives in excess of 800 calls per day with respect to dermatological issues and has a capacity to handle only about half of the inquiries.
Dr. Stockfleth’s research on dermatology, oncology and in particular, skin cancer, has been extensively published in peer-reviewed journals. He has contributed to the Journal of Infectious Diseases, International Journal of Cancer, Journal of Investigative Dermatology and The Lancet. He is also the former European President of Skin Care in Organ Transplant Patients Network (SCOPE). In 2008 he was one of the founders of the European Skin Cancer Foundation, which assists in developing and providing standardized treatments on a European level. Dr. Stockfleth graduated from the University of Hamburg and is a Jung-Foundation scholar.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181023006008/en/
Contacts:
MedX Health Corp
Scott Spearn, 905-670-4428 ext 229
President and CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com
- Published in Business, Life Sciences, MedX Health Corp., News Home, Technology
MedX Health closes first tranche of placement
Momentum Public Relations
Press Release: October 11, 2018
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an initial Closing of 2,106,250 Units, to raise $337,000 from accredited investors. The Company is planning to raise up to $2.5 million by issuance of up to 15,625,000 Units from the Placement Offering. Each Unit, priced at $0.16, comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at a price of $0.35 during the period up to three years from the closing date of the placement. The securities issued as a result of the Placement Offering will be restricted from trading for four months following each Closing. The Placement Offering is still open to subscribers, and further subscriptions may be accepted for further Closings. This Closing, and any further Closing of the Placement Offering, is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.
Following this Closing, MedX has 133,916,401 common shares issued and outstanding.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005958/en/
Contacts:
MedX Health Corp
Scott Spearn, 905-670-4428 ext 229
President and CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com
- Published in Business, Life Sciences, MedX Health Corp., News Home, Technology
Diagnos Five Years Ahead of Google in Diabtetic Retinopathy Screening Says Harvard Professor
Diabetic Retinopathy Market Predicted to Hit US$10.11 Billion by 2022
Diagnos Launches Hypertension Screening Application
AI Healthcare Applications Expected to Grow at 52% CAGR Between 2017-2022, Hitting US$7.98 Billion
Momentum Public Relations
Blog: September 24, 2018
On September 14th, 2018 Diagnos (TSXV: ADK) held an investor presentation at a downtown Montreal bistro for retail and institutional investors. Diagnos’ flagship product is CARA, computer aided retinal analysis, a cost efficient diabetic retinopathy screening application running on the company’s artificial intelligence platform Flaire. The company has been going from triumph to triumph this year. One indication of that was the presence of Chinese investment fund representatives.
During the presentation, recently appointed Diagnos Board member Dr. Reed Maclellan described the company’s technology as being “light years ahead of the competition. I was at a recent conference and nobody, not even Google can do what Cara can. Cara can detect macular degeneration. This is the only technology in the world that can do it. Diagnos is five years ahead of Google.”
Maclellan is an adjunct professor at both Harvard and the Boston Children’s Hospital where he teaches surgery. A microcirculation specialist, Dr. Maclellan also lectures internationally and frequently speaks at conferences of the American College of Surgeons, the Plastic Surgeons Research Council and the International Society of Vascular Anomalies.
Diagnos develops screening tools that help health care providers cut costs and make early diagnoses. Cara is designed to detect diabetic retinopathy and has the potential to prevent 85-90% of diabetes induced vision loss through early detection. At last count Cara has screened 222,034 patients, in 16 countries, using 131 screening sites. If untreated diabetic retinopathy leads to blindness.
The company is currently conducting its first Canadian pilot project in Montreal at CHUM, the Centre hospitalier de l’Universite de Montreal. If the pilot project is a success, Larente expects to be setting up Cara screening centres in hospitals and clinics across Quebec. CHUM has 35,000 diabetics, 80% of whom have never had a retina screening. Once you are a diabetic you face a 50% chance of going blind.
“Our job,” Larente, Diagnos’ president said in an earlier interview, “is to screen those 35,000 diabetics and send the ones that are critical right to the ophthalmology department and mange the other ones. Manage means you come every year and you get your test done.”
Once the pilot project is completed Larente expects to see Cara screening facilities in Quebec hospitals and just as a successful pilot project in Mexico led to a government contract, he expects the CHUM pilot project to result in a contract with the Quebec Ministry of Health.
“This will actually reduce the cost to the government because now you are going to manage the diabetic population. When you start to have retinopathy you can treat the patient. There is diet, there are vitamins. There are small inexpensive treatments to make sure it doesn’t go to the critical stage. There is a very effective laser treatment for bleeding.”
The diabetic retinopathy market is growing at 6.8% CAGR and according to a news release issued by Million Insights will grow from US$5.9 billion in 2014, to US$10.11 billion in 2022.
During the presentation, Diagnos president Andre Larente, announced that while the company intended to keep on marketing to government health agencies it also intended to beef up its approach to targets like hospitals and health care providers.
Drawing on his own experience, Maclellan described why AI powered medical devices had an initial slow adoption rates. “People were afraid it would take their jobs.” That has now changed. “Once one hospital starts using it, Cara adoption will snowball.”
To show just how much AI driven platforms are gaining traction in medicine at the beginning of 2018 Research House Frost & Sullivan predicted that by 2025, 85% of surgical procedures are likely to be done by robots.
According to Market and Markets, the market for artificial intelligence applications in healthcare will grow from US$667.1 million in 2016 to US$ 7.98 billion in 2022, growing at a CAGR of 52.68% during the forecast period.
Diagnos’ product line is expanding. In July the company launched the first application in its Cardio product line, Cara HTA. The application uses the same fundus camera used for diabetic retinopathy to screen for hypertensive retinopathy. Cara HTA also monitors the efficacy of blood pressure treatments which will allow doctors to monitor and adjust treatment as necessary.
From a revenue standpoint, Cara HTA offers the same form of recurring revenues that screening for diabetic retinopathy does. Once the screening has been initially performed patients will require additional screenings on an annual or as needed basis.
The hypertension market is huge. Almost one in two adult Americans, for example, suffer from high blood pressure, a precursor to strokes and heart attacks.
Diagnos also has a third product in development, Cara Cardio which will screen for cardiovascular disease and debut during 2019. In September Diagnos signed two agreements. The first was with another Montreal-based company Optina Diagnostics, to provide a telemedicine platform based on Cara for a period of three years. Optina will use Diagnos Cloud Services to upload images generated by Optina’s hyperspectral camera for the early detection of Alzheimer’s.
The company believes that the agreement will attract other biotech companies that need a telemedicine platform. Cara includes a telemedicine platform that allows all the medical professionals involved to see the same picture. Additionally the company has already successfully incorporated blockchain technology to maintain patient confidentiality.
In September the company also signed a three year agreement with American company 20/20NOW to provide diabetic retinopathy screening services. 20/20NOW is a pioneer in ocular telehealth.
September has been a good month for Diagnos, the future should be even better.
- Published in Blog, Diagnos, Life Sciences, News Home, Technology, Uncategorized
MedX Health appoints Spearn as CEO, director
Momentum Public Relations
Press Release: September 24, 2018
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces the following changes to its Board and Executive team, effective immediately. Scott Spearn, who joined the Company as President in April 2018 is taking on the additional role of Chief Executive Officer and is joining the Board of Directors. Rob von der Porten, previously the CEO, has been appointed as Chairman of the Board in place of Gary Van Nest who has retired from that position and remains as a director.
“With the recent launch of our DermSecure™ telemedicine platform and anticipating a global roll-out of this leading product, the transition of Scott’s role to CEO represents a natural evolution at MedX,” noted Rob von der Porten, MedX’s new Chairman. “Scott’s experience in building sales organizations and developing international markets in the medical device field will help accelerate our growth from our SIAscopy technology and our Therapeutic and Dental Laser products.”
Gary Van Nest noted, “On behalf of the Board, we want to thank Rob von der Porten for his leadership during challenging times over the past few years and developing with the MedX team solid product roadmaps such as the delivery of DermSecure™.
“I am excited to be taking on the CEO role, leading a dedicated team of hard-working people. MedX is a great Canadian company with innovative products and robust technology that is making a big difference in the health of people’s lives around the world,” said Mr. Spearn.
Mr. Spearn is a seasoned medical device executive with nearly 30 years of developing sustainable, trusted relationships with key opinion leaders, strategic partners and industry influencers. Before joining MedX, Mr. Spearn held a number of senior executive roles at a multi-national medical device company where he substantially grew revenues across several business divisions.
The Company has granted 1,000,000 share options to the incoming CEO, the options having an exercise price of $0.16, exercisable for a period of five years, and vesting over a one-year period.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005812/en/
Contacts:
MedX Health Corp
Scott Spearn, 905-670-4428 ext 226
President and CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com
- Published in Business, Life Sciences, MedX Health Corp., News Home, Technology
DIAGNOS to Provide Retinal Image Analysis using its AI Technology to 20/20NOW, the Leading Ocular Telehealth Provider in the United States
Momentum Public Relations
Press Release: September 18, 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today a three-year agreement to provide its CARA (Computer Assisted Retina Analysis) to 20/20NOW. 20/20NOW will use CARA to upload their retinal images and retrieve the results after analysis by our algorithms to detect anomalies caused by diabetic retinopathy in real time. Identifying diabetic retinopathy (“DR”) in its early stages, when it’s most treatable, is critical to prevent blindness and help at lowering health care costs.
“At DIAGNOS, we’re pleased to welcome an innovative company, 20/20NOW, as a new customer and business partner. We also want to extend a warm welcome to their network of more than 60 customers located across the United States. We will exclusively provide rapid and early detection of DR to their customers in the optical space. As 20/20NOW expands their network, we will provide them with fast and reliable detection of DR. As we introduce new healthcare applications, we will work with 20/20NOW to leverage their network and provide early detection of other illnesses to the benefit of their patients.” said Yves-Stephane Couture, Vice-President of Sales at DIAGNOS.
Telehealth industry veteran and 20/20NOW CEO, Chuck Scott, stated “Our mission at 20/20NOW is to expand access to comprehensive eye exams while also improving the standard of care, at a lower cost to our patients. Through the use of cutting-edge AI technology provided by DIAGNOS, our Ocular Telehealth eye exams represent a cost-effective tool to help solve one of the most pressing health care issue in our country today.”
Mr. Scott further stated “The opportunity exists to combine the use of AI and Ocular Telehealth to cost effectively screen and detect other critical health diseases beyond diabetic retinopathy. We believe there will be a vast array of ocular diseases that can be detected through AI and retinal screenings in the future. We look forward to partnering with DIAGNOS to bring these capabilities to market.”
About 20/20NOW
20/20NOW is the pioneer and innovator of ocular telehealth. Using state-of-the-art technology, proprietary software and patented exam processes, 20/20NOW provides comprehensive eye exams, including eye health screenings, via telehealth. The company’s telehealth model allows eye care professionals and optical retailers to provide their patients with increased access to high quality eye exams at a lower cost.
Additional information is available at www.for2020now.com.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
- Published in Business, Diagnos, Life Sciences, News Home, Technology
DIAGNOS Partners with Optina Diagnostics, a Montreal Based Company, to Provide a Web Platform for the Early Detection of Alzheimer Disease
Momentum Public Relations
Press Release: September 5, 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an agreement to provide a telemedicine platform based on CARA (Computer Assisted Retina Analysis) to Optina Diagnostics (“Optina”) for a period of 3 years. Optina will use DIAGNOS Cloud services to upload images generated by Optina’s hyperspectral camera for early detection of Alzheimer via key biomarkers in the retina of the eye.
The processed images will be available to be shared and further analysed by healthcare professionals and clinics in various locations. Optina will benefit from the high throughput of DIAGNOS CARA Cloud service as well as the ease of use of the teleophthalmology platform currently used by doctors and other medical professionals.
“At DIAGNOS, we are extremely happy to contribute to the success of innovative Quebec companies like Optina. Optina will leverage our experience and the high quality standard of CARA, a field proven platform approved for sale by the Food and Drug Administration in the United States, Health Canada and other countries’ homologation bodies. This partnership will foster more collaboration with other biotech firms and attract new clients in need of a telemedicine platform.” said Yves-Stephane Couture, Vice-President of sales at DIAGNOS.
“The partnership will greatly accelerate Optina’s commercialization of its Alzheimer diagnostic test, saving critical time to market while providing effective and efficient user experience.” said David Lapointe, President and CEO of Optina.
About Optina
Optina Diagnostics is a Montreal based company focused on the development of technology for the early detection of disease through hyperspectral imaging of the eye. With a first application in the early diagnosis of Alzheimer’s, Optina brings a radiomics approach to biomarker detection.
Additional information about Optina is available at www.optinadx.com.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele- ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
- Published in Business, Diagnos, Life Sciences, News Home, Technology